Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Corvatta

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2012
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma RegistryMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|February 23, 2011
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomideMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
British Journal of Haematology|November 28, 2008
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised studyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica|January 26, 2006
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II studyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Ejhaem|June 19, 2024
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in ItalyFrancesca Fazio, Maria Teresa Petrucci, Laura Corvatta, et al.
Blood|June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myelomaMassimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
British Journal of Haematology|April 26, 2002
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centresLivio Pagano, Luana Fianchi, Luca Mele, et al.
Cancers|November 13, 2025
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?Sonia Morè, Massimo Offidani, Laura Corvatta, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2025
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma PatientsSonia Morè, Massimo Offidani, Laura Corvatta, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2012
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma RegistryMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|February 23, 2011
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomideMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
British Journal of Haematology|November 28, 2008
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised studyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica|January 26, 2006
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II studyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Ejhaem|June 19, 2024
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in ItalyFrancesca Fazio, Maria Teresa Petrucci, Laura Corvatta, et al.
Blood|June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myelomaMassimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
British Journal of Haematology|April 26, 2002
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centresLivio Pagano, Luana Fianchi, Luca Mele, et al.
Cancers|November 13, 2025
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?Sonia Morè, Massimo Offidani, Laura Corvatta, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2025
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma PatientsSonia Morè, Massimo Offidani, Laura Corvatta, et al.
Pageof 5